Hemab Doses First Patient in Phase 1 Trial of HMB-003 for Heavy Menstrual Bleeding
COAG sits 78% above its 52-week low of $23.
Summary
Hemab has dosed the first healthy volunteer in its Phase 1 trial of HMB-003, a long-acting antifibrinolytic for heavy menstrual bleeding. The trial is a randomized, placebo-controlled, single-ascending-dose study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics. Preclinical data showed HMB-003 outperformed tranexamic acid and sustained activity for about a week in minipigs, supporting once-per-cycle dosing. This is a meaningful pipeline advancement for a company with a $1.9B market cap and $457.5M in cash. Results are expected no later than mid-2027, which will inform dose selection and expansion into other bleeding indications.
At the time of this announcement, COAG was trading at $40.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $23.00 to $55.42. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.